Separately, starting July 1, 2026, the Medicare GLP-1 Bridge, a national CMS demonstration, gives eligible Part D beneficiaries Wegovy, Foundayo, or the Zepbound KwikPen at a flat $50 per month through 2027
GLP-1 agonists are peptides that mimic the natural GLP-1 hormone present in the body to release insulin and suppress the release of glucagon in response to eating, thereby lowering blood sugar
If youre interested in learning more about how these groundbreaking medications can aid in your weight loss journey, or how the DrWell program can support your overall health, contact us today for a consultation
Nasal bioavailability is approximately 3%
Tirzepatide: available and gaining ground Tirzepatide is FDA-approved as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management)
How many calories should I eat on semaglutide